Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Orgenesis Inc is a biotechnology business based in the US. Orgenesis shares (ORGS) are listed on the NASDAQ and all prices are listed in US Dollars. Orgenesis employs 151 staff and has a trailing 12-month revenue of around $30 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $1.40 |
|---|---|
| 52-week range | $1.31 - $5.20 |
| 50-day moving average | $1.77 |
| 200-day moving average | $2.58 |
| Wall St. target price | $9.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.90 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.4 from 2022-10-03
| 1 week (2022-09-28) | -4.11% |
|---|---|
| 1 month (2022-09-02) | -26.70% |
| 3 months (2022-07-05) | -39.13% |
| 6 months (2022-04-04) | -58.21% |
| 1 year (2021-10-05) | -70.65% |
|---|---|
| 2 years (2020-10-05) | -73.18% |
| 3 years (2019-10-04) | 3.675 |
| 5 years (2017-10-02) | 211.11% |
| Revenue TTM | $30 million |
|---|---|
| Gross profit TTM | $35.5 million |
| Return on assets TTM | -20.33% |
| Return on equity TTM | -59.17% |
| Profit margin | -82.09% |
| Book value | $1.28 |
| Market capitalisation | $36.3 million |
TTM: trailing 12 months
We're not expecting Orgenesis to pay a dividend over the next 12 months.
Orgenesis's shares were split on a 1:12 basis on 16 November 2017. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orgenesis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Orgenesis shares which in turn could have impacted Orgenesis's share price.
Over the last 12 months, Orgenesis's shares have ranged in value from as little as $1.31 up to $5.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orgenesis's is 0.7223. This would suggest that Orgenesis's shares are less volatile than average (for this exchange).
Orgenesis Inc. , a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.